Dianthus Therapeutics, Inc. ((DNTH)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The CAPTIVATE study, officially titled ‘A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP),’ aims to assess the efficacy and safety of DNTH103. This study is significant as it targets CIDP, a chronic neurological disorder that affects the peripheral nerves, potentially offering new treatment options for patients.
The intervention being tested is DNTH103, administered both intravenously and subcutaneously. DNTH103 is designed to treat CIDP by reducing inflammation and demyelination in the peripheral nerves.
The study design is interventional with a randomized, parallel assignment. It employs triple masking, meaning the participant, investigator, and outcomes assessor are unaware of the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on February 10, 2025, with the primary completion date yet to be announced. The last update was submitted on July 25, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The market implications of this study are significant for Dianthus Therapeutics, Inc. (DNTH), as positive results could enhance stock performance and attract investor interest. The study’s progress is particularly relevant in the context of the competitive landscape of CIDP treatments, where new, effective therapies are in demand.
The CAPTIVATE study is currently ongoing, with further details available on the ClinicalTrials portal.